Leif Helth Jensen has more than 30 years of experience within the life science industry and been involved in a number of the most successful Danish Biotech companies. He has been the CEO of two Biotech companies (Cureon (now called Santaris Pharma) and Glycom), on the Board of Directors in more than 20 Biotech companies (including Genmab, Zealand Pharma, Cureon, Exiqon), Chairman in more than 10 companies (including Nobak, Bone Medical (Australia)) and been the co-founder of 4 Biotech companies (NeuroSearch, Zealand Pharma, Cureon and Synome (UK)). He has previously held other positions such as Director of Pharmacology at NeuroSearch, CEO of Danske Life Science, VicePresident Portfolio Management at LifeCycle Pharma and Investment Manager at CAT. He is currently the CEO of Rose Pharma and Leif Helth Care and Chairman in Synome (UK) and BluSense Diagnostics (Dk) and Board member in Lighthouse Quantum Technologies (Dk). He has a M.Sc. in Biology from the University of Copenhagen. He is a co-author of more than 50 peer-reviewed scientific papers and a co-inventor of 19 patent families.